Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study

BACKGROUND: Since giant cell tumors of bone (GCTB) and other giant cell rich tumors of bone (GCRTB) share the histological presence of osteoclastic giant cells and expression of RANK/RANKL, we hypothesized that GCRTB will respond similarly to denosumab as GCTB. The primary objective of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipplaa, Astrid, Schreuder, Willem H, Pichardo, Sarina E C, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628576/
https://www.ncbi.nlm.nih.gov/pubmed/37449658
http://dx.doi.org/10.1093/oncolo/oyad196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628576/
https://www.ncbi.nlm.nih.gov/pubmed/37449658
http://dx.doi.org/10.1093/oncolo/oyad196

Ejemplares similares